OK-31-67

+

Please type a plus sign (+) inside this box →

The

PTO/SB/21 (05-03) Approved for use through 04/30/2003, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no	persons are required	U.S. Patent and T	Approved for use through 04/30/2003. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE formation unless it displays a valid OMB control number.	
AUG 2 9 2007 RANSMITTAL FORM Line See used for all correspondence after initial filing)		Application Number	10/561,583	
		Filing Date	March 15, 2007	
		First Named Inventor	VAN WAMEL, WILLEM JAN BASTIAAN	
		Group Art Unit	Not yet assigned	
		Examiner Name	Not yet assigned	
Total Number of Pages in This Submission 3		Attorney Docket Number	ARSI-012	
Total Names of Section 110 Sections		ES (check all that apply)		
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement SB08A Form (total 2 pgs.) Certified Copy of Priority Documents Response to Missing Parts/ Incomplete Application	(for an Drawin Dr	n to Convert to a clonal Application of Attorney, Revocation to Corvers of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 2 References Return Postcard	
Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks			
SIGNA	TURE OF APPL	ICANT, ATTORNEY, O	RAGENT	
Signing Attorney/Agent (Reg. No.) CAROLL. FRANCIS	S, PH.D., 36,513 & FRANCIS, #1	∌ 1		
Signature Caul MIII				
Date August 29, 200				

This collection of information is required by 37 CFR 1.5. This information is required to obtain or retain a bonefit by the public which is to file (and by the USPTO) on process) an application. Confidentiality is governed by 38 U.S. C. 22 and 37 CFR 1.1.4 This collection is estimated to 12 minutes to complete, including eathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Giffort, U.S. Patent and Tademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, Va. 2231-3450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionner for Patents, P.O. Box 1450, Alexandria, Va. 2231-31450.

EXPRESS MAIL LABEL NO. EV 955 153 725 US

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

(*) Express Mail No. EV 955 153 725 US

SUPPLEMENTAL	Attorney Docket	ARSI-012
INFORMATION	First Named Inventor	VAN WAMEL, WILLEM JAN
DISCLOSURE STATEMENT	Application Number	10/561,583
Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Confirmation No.	6152
	Filing Date	March 15, 2007
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Title: "THERAPEUTIC USE OF LPI, A STAPHYLOCOCCAL LECTIN PATHWAY INHIBITOR IN INFLAMMATORY DISEASES"	

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. ASSI-OI2 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Carol L. Francis, Ph.D.

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

AUG 2 9 2007

PTO/SB/08a (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Not yet assigned

ARSI-012

Substitute for form flow DISCLOSURE

red to respond to a collection of information unless it contains a valid OMB control number

STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of

Under the Paper

Examiner

Signature

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number		Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials'	No.1			MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant
		Number-Kind Code ² (# know	n)		*	Figures Appear
		US-		-		
		US-				
		US-				

Examiner Name

Attorney Docket Number

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials'	No.1	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T ^e
					·	
						_

Exam Exam Exam Exam Exam Exam Exam Exam				
Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
)./	DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Hypothetical protein SA1754." Retrieved from EBI accession no. UNITPROT-Q99SU9 Database accession no. Q99SU9_STAAN;			
/	DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Fibrinogen binding protein." Retrieved from EBI accession no. UNITPROT:Q99UU9 Database accession no. Q99UU9_STAAN.	-		
	No.1	ngazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Hypothetical protein SA1754." Retrieved from EBI accession no. UNITPROT: Opps Support and accession no. Opps Support STAAN; DATABASE UnitProt [Online] 1 June 2001 (2001-06-01), "Fibrinogen linding protein." Retrieved from EBI accession no. INITPROTOCOULLIN Development of COURT IN COUNTRY C		

Date

06/08/2010

*FYAMINER: Initial if reference considered whether	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

/Patricia Duffy/

This collection of information is required by 37 CPR 1.97 and 1.88. The information is required to obtain or retain a bowful by the public which is to like (and by the USPTO to process) an application. Confidentiality is operand by \$5 U.S. C. 12 and 37 CPR 1.14. This collection is estimated to lake 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time pay unrequire to complete this form andord exaggestions for modulicing the burdent, should be sent the the Christ Information (U.S. Patient and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Commissional or for Patients, P.O. Box 1450, Alexandris, VA 22313-1450.